Jimenez-Zepeda Victor H, Chen Guanmin, Shaw Eileen, Farris Megan S, Cowling Tara, Tay Jason
Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada.
Cumming School of Medicine, University of Calgary, Calgary, Canada.
Leuk Lymphoma. 2022 Nov;63(11):2557-2564. doi: 10.1080/10428194.2022.2092852. Epub 2022 Jul 5.
The purpose of this study is to describe the real-world multiple myeloma (MM) population in Alberta by examining patient/clinical characteristics and the treatment landscape. A retrospective, observational study was conducted using province-wide, administrative health data from Alberta, Canada evaluating newly diagnosed MM (NDMM) patients. Between 1 April 2011 and 31 March 2017, 1377 treated NDMM cases were identified. Of those, 328 (23.8%) received an autologous stem cell transplant (ASCT) within the first year of diagnosis. In the ASCT group, 189 advanced to second-line (57.6%), 103 (32.6%) to third-line and 97 (29.5%) had four or more lines of therapy. In non-ASCT patients, 553 (52.7%) advanced to second-line, 238 (22.7%) to third-line, and 154 (14.7%) had 4 or more lines of therapy. We observed a significant treatment attrition rate in NDMM. Therefore, the use of best therapy upfront and novel strategies aiming to decrease attrition rates in MM is encouraged.
本研究的目的是通过检查患者/临床特征及治疗情况来描述艾伯塔省现实世界中的多发性骨髓瘤（MM）患者群体。我们利用加拿大艾伯塔省全省范围的行政卫生数据，对新诊断的MM（NDMM）患者进行了一项回顾性观察研究。在2011年4月1日至2017年3月31日期间，共识别出1377例接受治疗的NDMM病例。其中，328例（23.8%）在诊断后的第一年内接受了自体干细胞移植（ASCT）。在ASCT组中，189例进入二线治疗（57.6%），103例（32.6%）进入三线治疗，97例（29.5%）接受了四线或更多线的治疗。在未接受ASCT的患者中，553例（52.7%）进入二线治疗，238例（22.7%）进入三线治疗，154例（14.7%）接受了四线或更多线的治疗。我们观察到NDMM患者中有显著的治疗损耗率。因此，鼓励在MM治疗中尽早使用最佳疗法以及采用旨在降低损耗率的新策略。
